58 New Range of SARS-CoV-2 Spike Protein Products Launched
Amsbio has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non- specific binding and developed operational protocols saving you time and hassle.
Developed for immunocapture, cell stimulating, biopanning and flow cytometry applications these new products use biotinylated SARS-CoV-2 Spike protein pre-coupled to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample. Because Streptavidin has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the magnetic beads irreversibly.
The complex may be removed from the solution manually using a magnetic separator. The bound SARS-CoV-2 spike proteins can then be dissociated from the magnetic beads using an elution buffer. All magnetic bead products from AMSBIO are of uniform size, narrow size distribution with large surface area and unique surface coating, which delivers industry-leading performance and highly reproducible results. Amsbio also offers a Custom Magnetic Beads service to provide you with the best possible tools for your specific research project.
Amsbio has also introduced new SARS-CoV2 Spike S1 protein-coated and SARS-CoV2 Spike protein RBD-Coated microplates optimised for ELISA Assay and Biopannning. These assay kits employ a standard Indirect-ELISA format which provide a rapid quantification of Anti-SARS-CoV-2 antibodies or ACE-2 protein in serum by binding to Spike protein S1. Key advantages of these new plates include time saving (pre-coated and blocked), flexible experimental design (detachable 8-well strips) and that they are proven to eliminate problems associated with denaturing of the protein component of a conjugate upon binding. These new coated plates are ideal for binding anti-SARS2-CoV-2 antibodies or ACE2 protein that typically exhibit poor binding to polystyrene.
With infections spread globally, COVID-19 was declared a pandemic outbreak by the World Health Organization on 11 March 2020. The development of vaccines, diagnostics, and therapeutics is vital for the ongoing control of the outbreak. Amsbio provide an ever-expanding collection of tools for SARS-CoV-2 and Coronavirus research, including recombinant proteins, antibodies, inhibitor screening kits, and other assay kits.
More information online:
ilmt.co/PL/Ko1g 52603pr@reply-direct.com Instrumentation for High-Tech Analysis of Particle Shape and Size
Whether in the field of production and quality control, research, development or the analytical laboratory, particle measurement is essential in many areas. This requires reproducible results, as provided with FRITSCH Particle Sizers. With the completely revised ANALYSETTE 22 NeXT you choose according to your requirements: The ANALYSETTE 22 NeXT Micro has a measuring range of 0.5 - 1500 µm for all typical measurement tasks. The high-end instrument, ANALYSETTE 22 NeXT Nano, has an extra wide measuring range of 0.01 - 3800 µm for maximum precision and sensitivity for smallest particles and also has an additional detector system.
A particle size analyser can only be as good as its dispersion capabilities. Due to the ANALYSETTE 22 NeXT’s cleverly reduced design and robust engineering, the dispersion unit is particularly durable and practically maintenance-free. The complete absence of valves and movable seals in the sample circuit ensures that there are no dead spaces for sample material to settle. The powerful, adjustable-speed centrifugal pump distributes the sample uniformly in the entire circuit for stable measurements.
The ANALYSETTE 28 ImageSizer is the ideal Particle Sizer for all applications that require accurate and reproducible measuring results for both particle shape and size of powders and bulk solids as well as of suspensions and emulsions. The optical process of Dynamic Image Analysis provides results for a wide measuring range, delivers multiple shape parameters and evaluation possibilities for particle size. The measuring time depending on the sample quantity, is under 5 minutes. And the result is available immediately.
The ANALYSETTE 28 ImageSizer, in combination with the corresponding wet dispersion unit, is ideal for measurement of particle shape and size of suspensions and emulsions. Wet dispersion is particularly suitable for fine particles, poorly flowing, fine-agglomerating or sticky materials, which do not react in water or other liquids.
The ANALYSETTE 28 ImageSizer is the ideal Particle Sizer for fast analysis of particle size and shape of dry, free-flowing materials. Via the optical analysis of the particle shape and particle size, you can identify damaged particles, contaminates, agglomerates or oversized and undersized particles accurately and fast and view them completely uncomplicated in single images.
More information online:
ilmt.co/PL/4OVK and
ilmt.co/PL/m2Bp Characterising Virus and Virus-Like Particles
Postnova Analytics reports how its latest generation of Asymmetrical Flow Field Flow Fractionation (AF4) systems are providing labs worldwide with a uniquely powerful technique to characterise and quantitate virus and virus-like particles.
Virus and virus-like particles are widely used in the healthcare industry for vaccination via immune response stimulation. Because these particles are to be injected into patients there is a critical requirement for a technique that allows detection and separation of the monomeric, oligomeric and aggregated species in a typical formulation.
While Size Exclusion Chromatography (SEC) has been a traditional analytical technique used for this application it has significant limitations relating to the size exclusion limit of the separation column that restricts the upper molar mass and particle size range that can be measured.
By comparison, Asymmetrical Flow Field Flow Fractionation (AF4) is an advanced separation technique that can address the problems associated with SEC. In AF4, an open, unpacked separation channel is used in place of a packed column. The absence of a stationary phase in AF4 systems results in the ability to use a wider range of solvents, elimination of SEC shear force and matrix interaction effects as well as the ability to separate particles over a very wide size range, from 1 nm up to above 1 µm. These capabilities enable AF4 to provide a complete picture of virus and virus-like particles including monomer content, insoluble and soluble aggregates, as well as the subvisible particle fraction.
More information online:
ilmt.co/PL/Q0QP 52453pr@reply-direct.com
53021pr@reply-direct.com
NGS Panel for Constitutional Cytogenetics Launched
Oxford Gene Technology (OGT), A Sysmex Group Company, has launched a transformative next-generation sequencing (NGS) panel for constitutional cytogenetics research. The CytoSure™ Constitutional NGS Panel contains the most up-to-date, hand-curated content for intellectual disability (ID) and developmental delay (DD) research. Delivering accurate and reliable detection of copy number variations (CNVs), single nucleotide variations (SNVs), insertion/deletions (indels) and loss of heterozygosity (LOH) - including in mosaic samples - the panel combines the benefits of NGS and microarrays in one cost-effective assay. OGT’s CytoSure brand is renowned for excellence in constitutional cytogenetics, with its popular Constitutional v3 microarrays in wide use across major laboratories worldwide. There is a desire within constitutional genetics laboratories to transition to NGS technologies, however it has often been problematic to achieve accurate single-exon CNV and LOH detection on these platforms. OGT’s expertise combined with a long heritage in hybridisation technologies, design and software, has enabled the company to overcome this challenge, producing CNV data quality that is second to none. Data produced from the CytoSure Constitutional NGS panel is of the highest quality and shows excellent concordance with arrays. The intuitive, user-friendly software means there is no need for large bioinformatics teams to work alongside labs for data analysis.
The empirically-optimised CytoSure Constitutional NGS panel, designed in collaboration with leading cytogenetics experts and consortia, targets over 700 genes at the exon level. The panel has been rigorously tested in cytogenetics labs in order to ensure the highest possible performance and confidence in results. Alpha and beta triallists were particularly pleased with the detection capabilities and software ease of use. Designed to be run on the Illumina NextSeq™ or NovaSeq™, the CytoSure Constitutional NGS solution includes hybridisation capture baits, a complete library preparation kit (including hyb/wash buffer) and powerful complimentary analysis software for SNV, indel, CNV and LOH interpretation. OGT’s popular, easy-to-use Interpret software delivers confident, dependable data analysis and is a familiar visual platform for cytogeneticists - facilitating an easy transition to NGS.
Available at a similar cost to arrays (but yielding substantially more informative data), the CytoSure Constitutional NGS panel offers a more cost-effective solution than whole exome sequencing, reducing the costs of data storage whilst minimising detection of variants of uncertain significance (VUS) which are often seen as time consuming to analyse.
More information online:
ilmt.co/PL/4V5o 52313pr@reply-direct.com
INTERNATIONAL LABMATE - SEPTEMBER 2020
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
